Here's a sampling of our news reports.
BioPharm Insight’s news team compiles reports on indications, conferences, CRO activity, capital markets activity and other topics in the biopharmaceutical space. Subscribers receive real-time access to all reports, schedule a demo to learn how to become a subscriber.
22 Aug 2018
This report tracks 24 key events expected in September, 3Q and 2H including TG Therapeutics’ ublituximab in chronic lymphocytic leukemia, Vital Therapies’ ELAD in alcoholic hepatitis and Zealand Pharma’s dasiglucagon in severe hypoglycemia.
A sampling of headlines:
23 Jul 2018
This report compiles exclusive news and analysis based on interviews with key opinion leaders on market-moving events in the depression disorders space expected to occur in 2H.
26 Jun 2018
The report is a collection of articles that resulted from attending the 2018 American Society of Clinical Oncology (ASCO) conference. It includes coverage based on discussions with key opinion leaders about how the most important information coming out of the meeting will impact the drug development sector. It also includes trends and intel that the investigative journalist team gathered during the conference.
A sampling of headlines:
08 Mar 2018
Several companies are gearing up to report key data in ovarian and breast cancers in the upcoming months. This report highlights major developments expected to occur in the space during 1H18 and compiles published predictive intelligence based on interviews with key opinion leaders on these events.
22 Dec 2017
This report highlights pricing and reimbursement expectations for some key drugs in development. It also covers recent trends like the impact of Brexit on the UK’s pricing watchdog, NICE, and of Foundation Medicine’s diagnostic approval.
23 Nov 2017
BioPharm Insight attended the recent 2017 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Paris, 25-28 October. This news service discussed the latest treatments in MS with experts and gathered intelligence on key developments in the space from sources on the sidelines of the conference.
23 Oct 2017
This report is a collection of BPI’s articles related to our attendance at the 2017 ESMO (European Society for Medical Oncology) conference. It includes coverage based on our discussions with key opinion leaders about how the most important information coming out of the meeting will impact the drug development sector. It also includes trends and intel that the investigative journalist team gathered during the conference.
09 Sep 2017
This report compiles published predictive intelligence based on interviews with key opinion leaders on market-moving events expected to occur during October. It includes coverage on Flexion Therapeutics’ Zilretta for knee osteoarthritis, Alexion Pharmaceuticals’ Soliris for generalized myasthenia gravis and DBV Technologies’ Viaskin peanut for peanut allergy.
28 Jul 2017
This report is a collection of BPI’s articles related to our attendance of the 2017 ASCO (American Society of Clinical Oncology) conference. It includes coverage based on our discussions with key opinion leaders about how the most important information coming out of the meeting will impact the drug development sector. It also includes trends and intel that the investigative journalist team gathered during the conference.
Companies mentioned in the report include Roche, Bristol-Myers Squibb, AstraZeneca, Incyte, Pfizer, Abbvie, bluebird and more.
23 Jun 2017
This report focuses on pricing and reimbursement expectations for key drugs in development and analyses of important events and trends based on BPI’s discussions with key opinion leaders.
21 Feb 2017
In this report we highlight some of the major recent developments, important catalysts and current trends occurring in the breast cancer drug development field. While a whirlwind of activity in the breast cancer space is expected in 2017, the year will kick off with one of the most anticipated events, the outcome of Roche’s (VTX:ROG) APHINITY trial examining the benefit of adding Perjeta (pertuzumab), to Herceptin (trastuzumab) in the adjuvant HER2+ breast cancer setting.
31 Jan 2017
In this report we highlight some of the major recent developments, important catalysts and current trends occurring in the cardiology drug development field including Amgen’s announcement at the start of February that it met its primary and key secondary composite endpoints. Amgen’s news has significant implications for the entire PCSK9-inhibitor class and experts BPI spoke to said that anything lower than a 35% MACE reduction may mean that the cost outweighs the treatment benefit.
20 Jan 2017
This report, published every quarter, includes analytics on Financing, IPOs, Licensing and M&A deals based on BioPharm Insight’s data. It also highlights a selection of BPI’s editorial coverage on such activity based on interviews with C-level executives as well as trends based on conversations with industry experts.
07 Dec 2016
This report highlights some of the major recent developments and important catalysts occurring in the immuno-oncology field. It includes BPI news as well as predictive and competitive intelligence on clinical events in the space. The report also provides analytics on relevant details like sales forecasts, licensing deals, and more.
Companies included in this report: Advaxis, Amgen, Argos Therapeutics, AstraZeneca, bluebird bio, Bristol-Myers Squibb, GlaxoSmithKline, Juno Therapeutics, Kite Pharma, Merck, Novartis, Pfizer, Roche and more.
28 Nov 2016
This report serves as a cheat sheet for your attendance and preparation for the American Society of Hematology’s (ASH’s) 2016 annual meeting. It highlights some key presentations to be made on the most price-sensitive drugs in development. Additionally, you will find BPI’s coverage on these studies based on discussions with key opinion leaders.
07 Nov 2016
This report compiles published predictive intelligence based on interviews with key opinion leaders on market-moving events expected to occur during the next month and current quarter. It includes coverage on Roche’s ocrelizumab for RRMS and PPMS, Ophthotech’s Fovista for wet agerelated macular degeneration, Aradigm’s pulmaquin for non-cystic fibrosis bronchiectasis and other key situations.
14 Oct 2016
This report offers in-depth analysis of data from the CRO industry broken down by geography, therapeutic area and phases of development. Also included are analyses on the CRO industry’s acute clinical research understaffing issue, the growing sponsor demand for ‘unconventional’ Phase I-IV data collection, as well as Brexit’s potential impact on the volume of trial contracts. Lastly, the report includes articles based on interviewing drug development executives about their CRO needs and aggregated CRO appointment intelligence based on editorial coverage from 3Q16.
16 Sep 2016
While the political landscape takes shape before the US presidential elections, the cell therapy industry is facing potential shifts in regulatory framework that could allow developers earlier market access by bypassing certain clinical trials. Specifically, the proposed US REGROW bill -- which has gained renewed bipartisan interest but elicited concern from many cell therapy developers -- is unlikely to pass in Congress’s current session, but has success potential postelection, political consultants told BioPharm Insight.
JP Morgan Healthcare Conference and Biotech Showcase 2017
17 Jan 2017
This Postconference report serves as a round-up of news coverage at The 35th Annual J.P. Morgan Healthcare Conference and Biotech Showcase 2017 in San Francisco, California.
Companies Mentioned in this Report:
AbbVie, Accelovance, Advanced Accelerator, Alexion, Alkermes, Aurinia, BergenBio, BioMarin, Citius, Intercept, Juno, Keryx, Novaseek, Sarepta, Valeant, Vertex and more.
Competitive Intelligence Report
15 Nov 2016
This report is a sampling of news that the BPI investigative journalism team broke and competitive analysis they provided during 2016. The 10 articles included each cover therapeutic areas spanning solid tumors and blood cancer, central nervous system disorders, women's health as well as cardiovascular, genetic and orphan diseases. The editorial team reports on all therapeutic areas with active, material development.
Hot Topic Report
19 Aug 2016
In recent months, the orphan drug space has been under the spotlight more than usual with news from the FDA that the increasing number of orphan drug applications is impacting orphan drug review times. This is seen as proof that the Orphan Drug Act is having the desired effect of spurring drug developers into targeting rare diseases.
27 Jun 2016
Read this report to get our coverage related to the 2016 ASCO (American Society of Clinical Oncology) conference. Find out what key opinion leaders told BPI about key presentations and their impact on future drug development. In addition, see what experts told BPI on the status of currently ongoing trials and intelligence on terminated or soon to be initiated studies.
26 May 2016
According to BioPharm Insight data on expected sales data from 2018 to 2025 for five upcoming NASH therapies, Intercept Pharmaceuticals’ obeticholic acid is expected to generate the highest sales, forecasted at approximately USD 2bn by 2025. Its main competitors are Conatus’ emricasan, Galectin’s GR-MD-02, Galmed’s aramchol and Tobira’s cenicriviroc.
Read this report for more analytics on the NASH space and editorial coverage on key drugs in development.
13 May 2016
The preconference report is the ultimate guide for everyone planning to attend, and everyone interested in, the American Society of Clinical Oncology (ASCO) 2016 meeting. It highlights 34 key abstracts across 18 indications as highly important. Alongside the key abstracts are 24 BioPharm Insight articles based on interviews with Key Opinion Leaders.
Read the report to get forward-looking analyses on checkpoint inhibitors, other immune-oncology treatments, targeted therapies and hematological cancer drugs that will be showcased at ASCO.
M&A, Licensing, & IPO Report
22 Apr 2016
Deal activity in the first quarter of 2016 started much in the same way as 2015 ended. A handful of high profile acquisitions and IPOs helped prop up the biotech and pharma sector, but ultimately political rhetoric and global events subdued the prior five year bull run seen in biotech and pharma. Read the report to get a snapshot of M&A, Licensing and IPO editorial coverage over 1Q16 combined with the top deal activity datasets from BioPharm Insight’s database.
21 Apr 2016
As the number of approved biosimilars in the US and the EU is steadily increasing and expanding into additional disease areas, experts talked to BioPharm Insight about the subsequent inevitable pricing competition between originator and biosimilar products.
Experts also provided insight on the necessity for postmarket approval studies and the market uptake potential for certain approved or soon-to-be approved biosimilars, the impact of reference product patents on restricting US biosimilar competition as well as the viability of so-called “authorized biosimilars.”
07 Mar 2016
This report highlights the pricing and reimbursement landscape for certain drugs that were recently approved and are soon to be okayed. Read about payer restrictions CAR-T therapies are expected to face, Opdivo’s relatively smooth sailing in melanoma, anticipated pushback for Gilead’s most recent HIV drug and much more.
26 Feb 2016
Get our predictive intelligence on potentially market-moving clinical events in the neurology space as well as analytics on licensing deals and IPOs. The intel in this report covers migraine drugs, which could have a USD 8-10bn annual market, including CGRP antibodies from Eli Lilly and Amgen as well as CoLucid’s 5 HT1F receptor-targeted ditan. The report also highlights Adamas’ and Acorda’s assets for movement disorders; Jazz’s product for sleep disorders; and epilepsy drug candidates from Sage and UCB.
15 February 2016
15 Feb 2016
Check out this report for CRO opportunities the editorial team has uncovered as well as intelligence on CRO relationships and trial protocol amendments. You can find details on CRO needs for Eagle Pharma’s ecstasy-overdose trial as well as for a range of other indications in cancer, autoimmune and inflammatory diseases as well as men’s/women’s health.
Catalyst Monitor Report
12 Jan 2016
This report compiles expectations for 11 milestones expected in February and 1Q16. These include an FDA approval decision for Sarepta Therapeutics' eteplirsen in Duchenne muscular dystrophy, an EMA decision for Samsung Bioepis' Enbrel biosimilar and Alkermes' Phase III ALKS 5461 data in major depressive disorder.
18 Dec 2015
Read our report to find out what key opinion leaders have to say about the true market potential of Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda given associated toxicities. The report also addresses how physicians will need to adapt to using CAR-Ts in blood cancers and the technology’s potential in brain cancer. Additionally, therapeutic vaccines from Agenus, Bavarian Nordic, Celldex, Inovio and VentiRx are covered in this report.
23 Jun 2015
This report follows up on clinical trial results coming out of the European Hematology Association meeting. Besides a review of bluebird bio’s much awaited sickle cell disease data, the report also includes coverage on the firm’s beta thalassemia asset; pricing and reimbursement issues around hemophilia A and B products from Biogen and CSL, respectively; and business development intel on Emergent BioSolutions, Swedish Orphan Biovitrum and ProFactor Pharma.